#United States #New York #gene therapy #REGENXBIO #Stifel Conference

REGENXBIO to Participate in the Stifel 2026 Healthcare Conference

REGENXBIO Inc. (Nasdaq: RGNX), a leading player in the biotechnology industry, has made headlines with its announcement of participation in the upcoming Stifel 2026 Healthcare Conference. This key event, scheduled for November 11, 2026, promises to be a significant platform for discussing advancements in healthcare and biotechnological innovation.

Event Details

The fireside chat will take place at 9:20 a.m. ET, providing a valuable opportunity for industry stakeholders, investors, and the general public to gain insights into REGENXBIO’s progressive initiatives. Attendees can access a live webcast through the company’s investor relations section on their official website, www.regenxbio.com. Furthermore, an archived replay of the conversation will be available for about 30 days following the live event, ensuring that those unable to attend can still catch up on important discussions.

About REGENXBIO Inc.

Founded in 2009, REGENXBIO has been at the forefront of gene therapy advancements, pioneering the field of AAV (Adeno-associated Virus) gene therapy. The company is on a mission to enhance lives through innovative treatments, fully utilizing the curative potential of genetic interventions. With a robust pipeline focused on one-time treatments for rare and retinal diseases, REGENXBIO is reshaping how patients experience healthcare.

Among its noteworthy projects, the company’s lead product pipeline includes several key investigational gene therapies designed to tackle significant health challenges. These include:

• - RGX-202 for treating Duchenne Muscular Dystrophy.
• - clemidsogene lanparvovec (RGX-121), in collaboration with Nippon Shinyaku, targeting mucopolysaccharidosis type II (MPS II).
• - RGX-111, also partnered with Nippon Shinyaku, aimed at treating mucopolysaccharidosis type I (MPS I).
• - surabgene lomparvovec (ABBV-RGX-314), a therapy developed in collaboration with AbbVie for managing wet age-related macular degeneration (AMD) and diabetic retinopathy.

These investigational therapies have shown promise in clinical trials, where thousands of patients have benefited from the advanced AAV platform developed by REGENXBIO. By offering groundbreaking solutions, REGENXBIO aims to change healthcare’s landscape dramatically.

A Future-Focused Approach

As the Stifel 2026 Healthcare Conference approaches, interest in REGENXBIO’s presentation and its strategies to advance gene therapy is at an all-time high. With its dedication to innovative biotech solutions, REGENXBIO stands out not just as a participant but as a leader in transforming treatment paradigms for rare diseases.

For more detailed information regarding REGENXBIO's work and the advancements in gene therapy, visit their official website. The company’s commitment to improving patient outcomes continues to drive its initiatives and collaborations within the biotechnology space.

This event underscores the growing significance of discussions surrounding biotechnology and healthcare innovations. Stakeholders are encouraged to tune in and engage with the transformative ideas that REGENXBIO will present during the conference.

REGENXBIO’s ability to leverage gene therapy opens doors to new treatment methodologies, establishing it as a pivotal organization in biomedicine’s future. This conference will serve as a prime opportunity to witness how the company envisions the next steps in enhancing health outcomes for diverse patient populations.